|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Therefore, C57BL/6 wild type (WT) and Nrf2 knockout mice were induced to diabetes by streptozotocin, in the presence or absence of a 24-week treatment with EGCG.
|
28457936 |
2017 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Conversely, MG scavengers (such as N-acetylcysteine, aminoguanidine or metformin) or Nrf2/Glo1 activators (such as trans-resveratrol / hesperetin) are shown to be useful in preventing MG-induced cardiovascular and renal complications in diabetes.
|
30179128 |
2018 |
|
Diabetes
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In the experimental model of streptozotocin-induced diabetes in apolipoprotein E-deficient mice, treatment with tBHQ increased Nrf2 activity in macrophages and vascular smooth muscle cells within atherosclerotic lesions.
|
30108504 |
2018 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Therefore, C57BL/6 Nrf2 knockout (KO) and wild type (WT) mice were induced to diabetes by streptozotocin, and were treated in the presence or absence of NaB, for 20 weeks.
|
29964168 |
2018 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
NRF2 activation represents a potential novel approach in the treatment and prevention of obesity and diabetes.
|
21161163 |
2011 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thus, the present review aims to explore the relationship between free radicals, diabetes and its associated complications with respect to the genetic makeup of Nrf2/ARE regulated genes in an effort to expand treatment options.
|
23834171 |
2013 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
A possible compensatory mechanism for reduced gene expression of antioxidant enzymes is proved to be nuclear translocation of redox-sensitive Nrf2 and NFκB in diabetes which is confirmed by the increase in nuclear and decrease in cytoplasmic protein levels of Nrf2 and NFκB.
|
24740756 |
2014 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Because IL-1RA protects, maintains, and stimulates β-cell function in humans and Nrf-2‒Keap-1‒ARE protects β cells in animals with experimental diabetes, these actions of exenatide may contribute to a potential protective effect on β cells in diabetes.
|
29346597 |
2018 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
These findings support the potential of Nrf2 as a therapeutic target for the prevention and treatment of inflammation- and obesity-associated syndromes, including diabetes and atherosclerosis.
|
30913518 |
2019 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Nrf2 has been shown as a promising therapeutic target in various human diseases including diabetes.
|
28343084 |
2017 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Insulin is a potential antioxidant for diabetes-associated cognitive decline via regulating Nrf2 dependent antioxidant enzymes.
|
29793180 |
2018 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
This review discusses the concept that Nrf2/HO-1 acts as a 'therapeutic funnel' through which a range of natural and synthetic anti-oxidants may drive M1 to M2 switching and improved kidney function in diabetes.
|
30014796 |
2018 |
|
Diabetes
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Since nuclear factor E2-related factor 2 (Nrf2) controls the expression of antioxidant- and detoxification genes, it is hypothesized that targeted activation of Nrf2 using phytochemicals is likely to protect pancreatic β-cells, from oxidative damage, thereby mitigates the complications of diabetes.
|
30745874 |
2018 |
|
Diabetes
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Decreased Nrf2 activity represses the transcription of many antioxidant enzyme genes and alters the redox-balance up on diabetes.
|
25674242 |
2014 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Exploiting the dual action of natural Nrf2 inducers may provide a novel therapeutic strategy for restoring cellular redox homeostasis in aging and cardiovascular related diseases such diabetes, atherosclerosis and stroke.
|
22575091 |
2012 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
HDAC3 inhibition in diabetic mice may activate Nrf2 preventing diabetes-induced liver damage and FGF21 synthesis and secretion leading to aortic protection.
|
29634312 |
2018 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Therapies targeting Nrf2 activation, including epigenetic modifications, have potentional to prevent mitochondrial damage and inhibit the development, and progression of this sight-threatening disease which most of the patients get after 20-25 years of diabetes.
|
28012783 |
2017 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
The interaction of diabetes and/or sulforaphane with contrast media on Nrf2 regulation is not yet understood.
|
31173751 |
2019 |
|
Diabetes
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Polymorphisms in NRF2 and its target antioxidant genes: HMOX-1, NQO1, and MT, have been associated with cardiovascular diseases (CVDs) and diabetes in various ethnic groups, however, with variable results.
|
31332605 |
2020 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
The transcriptional factor Nrf2 regulates the expression of Gclc, the enzyme important in the biosynthesis of GSH, and in diabetes the binding of Nrf2 at the antioxidant response element region 4 (ARE4) is decreased.
|
25016074 |
2014 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
The present review provides an overview on the role of Nrf2 in type 1 diabetes and explores if it could be a potential target for the treatment of diabetes and related complications.
|
30359563 |
2019 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Furthermore, we discuss the role of NRF2 in cancer, neurodegeneration, and diabetes as well as cardiovascular, kidney, and liver disease, with a special emphasis on NRF2-based therapeutics, including those that have made it into clinical trials.
|
30256716 |
2019 |
|
Diabetes
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Thus we propose that Cx43 might enhance the activation of Nrf2/ARE pathway by means of inhibiting c-Src activity to hinder the nuclear export of Nrf2, and then reduce expression of FN, ICAM-1 and TGF-β1, ultimately attenuating renal fibrosis in diabetes.
|
27840317 |
2017 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study identifies Nrf2 plays a central role in skewing Th1 and Th2 dominance in the progression of diabetes.
|
29572460 |
2018 |
|
Diabetes
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Several activators of Nrf2 are known to combat diabetes induced endothelial dysfunction and few are currently in clinical trials.
|
31838079 |
2020 |